Clik here to view.
Genzyme Expects FDA Review of Myozyme Factory by Thanksgiving Weekend
Luke Timmerman If Genzyme gets its way, it will be able to start selling larger amounts of Myozyme in the U.S. by the end of this year. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:GENZ])...
View ArticleClik here to view.
FDA Panel Gives Nod to Genzyme Osteoarthritis Treatment
Ryan McBride An FDA advisory panel has voted 5-0 in favor of recommending approval of Cambridge, MA-based Genzyme’s (NASDAQ:GENZ) osteoarthritis treatment hylan GF 20 (Synvisc-One) in single...
View ArticleClik here to view.
Genzyme Nabs Two Key Regulatory Approvals, Expected to Trigger Revenue Growth
Ryan McBride Genzyme has picked up a pair of long-awaited regulatory approvals for two products that are key to the firm’s growth. The Cambridge, MA-based biotech powerhouse (NASDAQ:GENZ) says that...
View ArticleClik here to view.
Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga
Ryan McBride Alexis Borisy stepped down from his chief executive role at drug developer CombinatoRx (NASDAQ:CRXX) last week after nine years on the job. His departure was revealed on the same day as...
View ArticleClik here to view.
ConforMIS Shapes Corporate Expansion with $50M D Round
Ryan McBride Burlington, MA-based ConforMIS has tapped government and private funds around the globe to raise $50 million, providing a huge financial boost to expand its business of providing patients...
View ArticleClik here to view.
Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial
Arlene Weintraub [Updated 5/30/12 8:30 am. See below.] Today Woburn, MA-based Flexion Therapeutics announced that its treatment for osteoarthritis met its goal of significantly relieving joint pain in...
View ArticleClik here to view.
Flexion Therapeutics Secures $20 Million to Fight Osteoarthritis
Catherine Arnst [Corrected 12/04/12, 9:08 a.m. See below.] Flexion Therapeutics, based in Woburn, MA, said today that it has raised $20 million in a Series B financing led by Novo Ventures, a new...
View ArticleClik here to view.
East Coast Life Sciences Roundup: Zafgen, Moderna, Merck, More
Catherine Arnst —Obesity is paying off for Cambridge, MA-based Zafgen. On Tuesday the company said it closed on $21 million in a Series D equity funding to support continued development of its obesity...
View ArticleClik here to view.
Flexion’s Long-Lasting Steroid Injection Hits Mark in Phase 2 Trial
Ben Fidler [Updated 12 pm with correction] Flexion Therapeutics’ transformation into an osteoarthritis specialist continued gaining traction today, as the Burlington, MA-based company moved its most...
View ArticleClik here to view.
Flexion Files for IPO, Seeks $86M to Develop Osteoarthritis Drugs
Ben Fidler (Corrected, 2/12/14 at 12:11 pm ET) Flexion Therapeutics today became the latest biotech to jump into the IPO queue, looking to public investors to help bankroll the development of its...
View ArticleClik here to view.
East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More
Ben Fidler The (entire) biotech world is preparing to descend on San Francisco next week for the annual J.P. Morgan Healthcare bonanza. No surprise, then, that a flood of news hit the wires just...
View ArticleClik here to view.
Ampio Pharmaceuticals Starts Final Study for Osteoarthritis Treatment
Michael Davidson Ampio Pharmaceuticals thinks it has a new way to combat joint pain caused by osteoarthritis, and the growing Colorado biotech company is spending millions so it can hit the ground...
View ArticleClik here to view.
Flexion Prices IPO at $13, Heads to Nasdaq Tomorrow
Ben Fidler Flexion Therapeutics is set to become the latest biotech to debut on the Nasdaq. The Burlington, MA-based company, which is developing a group of osteoarthritis drugs, priced its IPO late...
View ArticleClik here to view.
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More
Ben Fidler (Updated, 9:05 am ET) The East Coast got buried in snow this week—again—but biotech activity was raging regardless. More IPOs priced (of course). A new high-profile startup emerged from...
View ArticleClik here to view.
East Coast Biotech Roundup: Sigal, Radius, SHIN-NY, & More
Ben Fidler Perhaps the biggest story in the biotech world this week came out west, where Brisbane, CA-based Intermune (NASDAQ: ITMN) nailed a big late-stage study and saw its shares soar more than 160...
View ArticleClik here to view.
East Coast Biotech Roundup: Unum, RaNA, Maxwell, Biogen, & More
Ben Fidler Over the next few days, it’s all about blood cancer: biotechs will jostle for the limelight at American Society of Hematology’s annual meeting in San Francisco, which kicks off tomorrow...
View ArticleClik here to view.
East Coast Biotech Roundup: Sync Project, Epizyme, Bristol & More
Ben Fidler If you missed our latest biotech event, “New York’s Life Science Disruptors” this past Thursday, don’t worry—we’ve got you covered. This week we’ll post an overview of the festivities,...
View ArticleClik here to view.
East Coast Biotech Roundup: Homology, Biogen, Intellia & More
It’s not a stretch to say that the progress of a gene editing technology known as CRISPR-Cas9 will be one of the most closely watched biotech stories of this decade. And two important developments...
View ArticleClik here to view.
Regeneron, in Pain Drug Race With Pfizer & Lilly, Gets $250M From Teva
Millions of people in the U.S. suffer from chronic forms of pain, but the treatment options aren’t great. Regeneron Pharmaceuticals is locked in a race with Eli Lilly and Pfizer to develop an...
View ArticleClik here to view.
After Strong 2017, Biotechs & Medtechs Start ’18 with Venture, IPO News
Life science companies are continuing to raise cash, keeping pace with the financing trends of recent years. Fourth quarter figures are still being tallied but in the third quarter, 171 companies...
View Article
